Lidocaine Hydrochloride Injection Shortage Update
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of Lidocaine Hydrochloride Injection, affecting some presentations used in anesthesia and pediatric care, with varying availability from manufacturers.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Lidocaine Hydrochloride Injection.
Lidocaine Hydrochloride Injection Shortage
What's in Shortage
The generic drug name is Lidocaine Hydrochloride Injection. Brand names include LIDOCAINE HYDROCHLORIDE, XYLOCAINE MPF, LIDOCAINE HYDROCHLORIDE AND DEXTROSE, XYLOCAINE, and LIDOCAINE. The dosage form is Injection. This shortage is currently ongoing, with the initial posting date of 02/22/2012 and last updated on 03/27/2026. It falls under the therapeutic categories of Anesthesia and Pediatric.
Which Manufacturers Are Affected
Several manufacturers are impacted. Hospira, Inc., a Pfizer Company has some presentations available (e.g., Lidocaine Hydrochloride, Injection, 40 mg/2 mL) and others unavailable (e.g., due to discontinuation or manufacturing delays). Fresenius Kabi USA, LLC has some unavailable (e.g., Expected recovery: TBD) and others available with notes to check wholesalers. Baxter Healthcare has presentations available. Contact information includes Hospira at 844-646-4398, Fresenius Kabi at 888-386-1300, and Baxter at 888-229-0001.
Why There's a Shortage
For some presentations, the shortage is due to manufacturing delays or discontinuation of the manufacture of the drug, as reported by the manufacturers. For others, no specific reason was provided beyond expected recovery dates or notes.
What Patients Should Do
If you depend on this medication, we recommend speaking with your pharmacist to check for availability and discuss options. You may also contact the relevant manufacturer for updates. Please remember that this article is for informational purposes only; patients should consult their healthcare provider for any medical advice or changes to their treatment.
Source
This information is from the FDA Drug Shortage Database, with the shortage status last updated on 03/27/2026.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,799 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.